Delhi 10 Years of Experience Oncology | Hemato-Oncology | Organ Transplant | Haematology and BMT
Dr. Akash Khandelwal is a senior Oncologist at Max Hospital, with deep expertise in the medical management of cancer across multiple tumour types. With over 15 years of oncology practice, Dr. Khandelwal is recognised for experience in chemotherapy, targeted therapy, immunotherapy protocols, and the management of treatment-related complications. Trained at India’s premier cancer institutions and with international exposure to evidence-based oncology practice, Dr. Khandelwal brings both technical skill and compassionate patient-centred care to complex oncology cases. A growing number of patients from Kazakhstan, Uzbekistan, and Russia seek cancer treatment at Max Hospital, drawn by 5-year survival rates matching European centres, access to the same immunotherapy agents used globally, and costs 60–70% lower than in Germany or Turkey. MediKaya Healthcare coordinates all Russian-language consultation, visa support, and accommodation for CIS cancer patients.
Experience Overview
Work Experience:
Achievements:
Dr. Akash Khandelwal specialises in the diagnosis and management of:
Patients from Kazakhstan, Uzbekistan, Russia and across the CIS region choose Dr. Akash Khandelwal at Max Hospital because:
India’s top cancer hospitals achieve 5-year survival rates of 80%+ for breast cancer — significantly above the 43% average in Russia and 60–65% in Kazakhstan. Patients access the same treatments available in Germany and the USA (proton therapy, immunotherapy, CAR-T cell therapy) at 60–70% lower cost. Waiting time for oncology consultation in India: 48–72 hours. In Kazakhstan: 3–6 months.
Through MediKaya Healthcare, all international patients from CIS countries receive dedicated Russian-speaking coordination from the moment of first inquiry through to post-treatment follow-up. Dr. Khandelwal’s team at Max Hospital is experienced in treating international patients and ensures all communication, medical reports, and treatment plans are clearly explained in Russian.
Professional Memberships
Awards:
Specialty Interests:
Languages Spoken
A: Yes. JCI-accredited hospitals with dedicated international oncology teams, Russian-speaking coordinators, and 24-hour patient support. Hospitals like BLK-Max, Medanta, and Max have treated thousands of CIS cancer patients with documented outcomes.
A: Chemotherapy in India costs 50–70% less than in Kazakhstan’s private hospitals. A full course of carboplatin-paclitaxel chemotherapy in India is approximately $800–$1,500 per cycle vs $2,500–$4,000 per cycle privately in Kazakhstan.
A: Yes. Immunotherapy drugs including pembrolizumab (Keytruda), nivolumab (Opdivo), and others are available at major Indian hospitals. Generic versions approved by Indian regulators cost 80% less than branded versions in CIS countries.
A: Send your biopsy reports, PET-CT or CT scans, histopathology reports, and current treatment plan to MediKaya Healthcare via WhatsApp or email. An Indian oncologist will review and provide a second opinion report within 48 hours — free of charge.
A: Yes, in most cases. Indian oncologists review the existing protocol and either continue it or recommend modifications. All communication with your Kazakhstan oncologist can be coordinated by MediKaya Healthcare.
Доктор Тежиндер Катария — председатель отдела онкологии и лучевой терапии в Medanta The Medicity, Гургаон. Один из ведущих специалистов Индии по лучевой терапии, включая IMRT, IGRT, VMAT и стереотаксическую радиохирургию. Стоимость полного курса лучевой терапии в Индии: $2 500–5 500. В Казахстане: $8 000–14 000 (при ограниченном доступе к современным технологиям). В Германии: $20 000–40 000. Начало лечения: через 3–7 дней после прибытия. Отправьте ваш диагноз и МРТ-снимки — бесплатная консультация за 48 часов.